Keith A.A. Fox, MBChB; Jean-Pierre Bassand, MD; Shamir R. Mehta, MD; Lars Wallentin, MD, PhD; Pierre Theroux, MD; Leopoldo Soares Piegas, MD, PhD; Vicent Valentin, MD; Tiziano Moccetti, MD; Susan Chrolavicius, BA; Rizwan Afzal, MSc; Salim Yusuf, MD, DPhil; on behalf of the OASIS 5 Investigators
A recent randomized, controlled trial, the Fifth Organization to Assess Strategies in Acute Ischemic Syndromes (OASIS 5) trial, reported that major bleeding was 2-fold less frequent with fondaparinux than with enoxaparin in acute coronary syndromes (ACS). Renal dysfunction increases the risk for major bleeding.
To compare the efficacy and safety of fondaparinux and enoxaparin over the spectrum of renal dysfunction observed in the OASIS 5 trial.
Subgroup analysis of a randomized, controlled trial.
Patients presenting to the hospital with nonâ€“ST-segment elevation ACS.
19Â 979 of the 20Â 078 patients in the OASIS 5 trial in whom creatinine was measured at baseline.
Death, myocardial infarction, refractory ischemia, and major bleeding were evaluated separately and as a composite end point at 9, 30, and 180 days. Glomerular filtration rate (GFR) was calculated by using the Modification of Diet in Renal Disease formula.
The absolute differences in favor of fondaparinux (efficacy and safety) were most marked in patients with a GFR less than 58 mL/min per 1.73 m2; the largest differences occurred in major bleeding events. At 9 days, death, myocardial infarction, or refractory ischemia occurred in 6.7% of patients receiving fondaparinux and 7.4% of those receiving enoxaparin (hazard ratio, 0.90 [95% CI, 0.73 to 1.11]); major bleeding occurred in 2.8% and 6.4%, respectively (hazard ratio, 0.42 [CI, 0.32 to 0.56]). Statistically significant differences in major bleeding persisted at 30 and 180 days. The rates of the composite end point were lower with fondaparinux than with enoxaparin in all quartiles of GFR, but the differences were statistically significant only among patients with a GFR less than 58 mL/min per 1.73 m2.
Subgroup analyses warrant caution; the study was powered to detect noninferiority at 9 days. Fondaparinux is not approved for use in patients with ACS in the United States.
The benefits of fondaparinux over enoxaparin when administered for nonâ€“ST-segment elevation ACS are most marked among patients with renal dysfunction and are largely explained by lower rates of major bleeding with fondaparinux.
Fox KA, Bassand J, Mehta SR, Wallentin L, Theroux P, Piegas LS, et al. Influence of Renal Function on the Efficacy and Safety of Fondaparinux Relative to Enoxaparin in Non–ST-Segment Elevation Acute Coronary Syndromes. Ann Intern Med. 2007;147:304–310. doi: 10.7326/0003-4819-147-5-200709040-00005
Download citation file:
Published: Ann Intern Med. 2007;147(5):304-310.
Acute Coronary Syndromes, Cardiac Diagnosis and Imaging, Cardiology, Coronary Heart Disease, Emergency Medicine.
Results provided by:
Copyright © 2019 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use